Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Namodenoson for non-alcoholic steatohepatitis
2023-510548-19-00Phase 2Authorised
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Namodenoson with Placebo (2 arms). Primary endpoint: Histologic response. Planned start Mar 2023; status: authorised.
02
Drugs
namodenoson
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2023-510548-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510548-19-00.